<DOC>
	<DOCNO>NCT01872689</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety lebrikizumab monotherapy absence background idiopathic pulmonary fibrosis ( IPF ) therapy combination therapy pirfenidone background therapy participant idiopathic pulmonary fibrosis . Participants randomize receive either lebrikizumab placebo subcutaneously ( SC ) every 4 week .</brief_summary>
	<brief_title>A Study Lebrikizumab Participants With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis IPF within previous 5 year time screen confirm baseline FVC &gt; /=40 % le equal ( &lt; /= ) 100 % predict screen Stable baseline lung function evidence difference le ( &lt; ) 10 % FVC ( liter ) measurement screen Day 1/Visit 2 prior randomization Diffusion capacity lung carbon monoxide &gt; /=25 % &lt; /=90 % predict screening Ability walk &gt; /=100 meter unassisted 6 minute Cohort A : No background IPF therapy &gt; /=4 week allow prior randomization throughout placebocontrolled study period Cohort B : Tolerated dose pirfenidone &lt; /=2403 milligram daily ( mg/QD ) &gt; /=4 week require prior randomization throughout placebocontrolled study period History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Evidence know cause interstitial lung disease ( ILD ) Lung transplant expect within 12 month screen Evidence clinically significant lung disease IPF Post bronchodilator force expiratory volume 1 second ( FEV1 ) /FVC ratio &lt; 0.7 screen Positive bronchodilator response , evidence increase &gt; /=12 % predict 200 milliliter ( mL ) increase FEV1 FVC Class IV New York Heart Association chronic heart failure historical evidence leave ventricular ejection fraction &lt; 35 % Hospitalization due exacerbation IPF within 4 week prior screen Known current malignancy current evaluation potential malignancy Listeria monocytogenes infection active parasitic infection within 6 month prior randomization Active tuberculosis require treatment within 12 month screen Known immunodeficiency , include limited human immunodeficiency virus ( HIV ) infection Past use antiinterleukin ( IL ) 13 antiIL14/IL13 therapy , include lebrikizumab Evidence acute chronic hepatitis know liver cirrhosis Exclusions Limited Cohort B : Known achalasia , esophageal stricture , esophageal dysfunction sufficient limit ability swallow oral medication Tobacco smoking use tobaccorelated product within 3 month screen unwillingness avoid smoking throughout study period Known suspect peptic ulcer Any condition , assess investigator , might significantly exacerbate know side effect associate pirfenidone Creatinine clearance &lt; 40 mL/minute , calculate use CockcroftGault formula Use follow therapy within 4 week randomization ( Day 1/Visit 2 ) study Strong inhibitor CYP1A2 ( Cytochrome P450 family 1 subfamily A member 2 ) ( example : fluvoxamine enoxacin ) Moderate inducer CYP1A2 ( limited tobacco smoking tobaccorelated product )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>